1. Home
  2. ANIK vs CGEN Comparison

ANIK vs CGEN Comparison

Compare ANIK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANIK
  • CGEN
  • Stock Information
  • Founded
  • ANIK 1983
  • CGEN 1993
  • Country
  • ANIK United States
  • CGEN Israel
  • Employees
  • ANIK N/A
  • CGEN N/A
  • Industry
  • ANIK Medical/Dental Instruments
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ANIK Health Care
  • CGEN Health Care
  • Exchange
  • ANIK Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • ANIK 157.8M
  • CGEN 167.4M
  • IPO Year
  • ANIK 1993
  • CGEN 2000
  • Fundamental
  • Price
  • ANIK $9.65
  • CGEN $1.45
  • Analyst Decision
  • ANIK Buy
  • CGEN
  • Analyst Count
  • ANIK 1
  • CGEN 0
  • Target Price
  • ANIK $15.00
  • CGEN N/A
  • AVG Volume (30 Days)
  • ANIK 160.8K
  • CGEN 192.2K
  • Earning Date
  • ANIK 07-30-2025
  • CGEN 08-06-2025
  • Dividend Yield
  • ANIK N/A
  • CGEN N/A
  • EPS Growth
  • ANIK N/A
  • CGEN N/A
  • EPS
  • ANIK N/A
  • CGEN N/A
  • Revenue
  • ANIK $114,548,000.00
  • CGEN $22,144,000.00
  • Revenue This Year
  • ANIK N/A
  • CGEN N/A
  • Revenue Next Year
  • ANIK $9.70
  • CGEN $105.77
  • P/E Ratio
  • ANIK N/A
  • CGEN N/A
  • Revenue Growth
  • ANIK 16.52
  • CGEN N/A
  • 52 Week Low
  • ANIK $7.87
  • CGEN $1.13
  • 52 Week High
  • ANIK $26.48
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • ANIK 53.23
  • CGEN 44.49
  • Support Level
  • ANIK $8.22
  • CGEN $1.40
  • Resistance Level
  • ANIK $9.25
  • CGEN $1.56
  • Average True Range (ATR)
  • ANIK 0.45
  • CGEN 0.06
  • MACD
  • ANIK 0.16
  • CGEN 0.00
  • Stochastic Oscillator
  • ANIK 97.19
  • CGEN 31.25

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: